Fundraising Fox

Luminopia

Aspen, US · Founded 2015 · Delaware corporation · 6 known investors

luminopia.com

Luminopia develops software-based therapeutics for neuro-visual disorders that stem from deficiencies in the brain rather than the eyes, generating therapeutic visual stimuli delivered through a virtual reality headset. Its lead product treats amblyopia, and serves as proof-of-concept for a broader platform targeting conditions such as brain-based vision loss in patients.

BiotechDigital HealthMedical Devicesin /luminopia@luminopia

Founders & leadership

DA
DEAN A. TRAVERSExecutive Officer, Director
SX
SCOTT XIAOExecutive Officer, Director
AW
ALEXANDER WENDLANDExecutive Officer, Director
SX
Scott XiaoCo-Founder & CEO
DT
Dean TraversCo-Founder
BR
Brion RaymondCBO
DM
Drew MoweryVP of Commercial Strategy
HW
Hank WuCOO
SA
Sunny AtwalVP of Engineering

Investors · 6

Reported raises · per SEC filings

Form D private placements
$15.8MraisedJun 2023 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Scott XiaoExecutive Officer, Director
  • Casey TanseyDirector
  • Robert LangerDirector
  • Dean TraversDirector
  • William DaiDirector
  • Mark JacobsteinDirector
Offering amount
$16.8M
Amount sold
$15.8M
First sale
Jun 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$4.1MraisedOct 2022 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeffrey DunnDirector
  • Scott XiaoExecutive Officer, Director
  • Dean TraversDirector
  • Robert LangerDirector
  • Mark JacobsteinDirector
  • Michelle LeeDirector
  • William DaiDirector
Offering amount
$5.1M
Amount sold
$4.1M
First sale
Oct 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$11.1MraisedDec 2019 · 29 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Scott XiaoExecutive Officer
  • Mark JacobsteinDirector
  • Jeffrey DunnDirector
  • Dean TraversExecutive Officer, Director, Promoter
  • Joi ItoDirector
  • Robert LangerDirector
Offering amount
$13.6M
Amount sold
$11.1M
First sale
Nov 2019
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$3.6MraisedSep 2017 · 8 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • SCOTT XIAOExecutive Officer, Director
  • ALEXANDER WENDLANDExecutive Officer, Director
  • MARK DOCKSERExecutive Officer
  • DEAN A. TRAVERSExecutive Officer, Director, Promoter
Offering amount
$5.1M
Amount sold
$3.6M
Minimum investment
$10K
First sale
Jun 2017
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$1.3MraisedSep 2017 · 3 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • SCOTT XIAOExecutive Officer, Director
  • MARK DOCKSERExecutive Officer
  • DEAN A. TRAVERSExecutive Officer, Director, Promoter
  • ALEXANDER WENDLANDExecutive Officer, Director
Offering amount
$2M
Amount sold
$1.3M
Minimum investment
$25K
First sale
Sep 2017
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$410KraisedDec 2016 · 8 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • SCOTT XIAOExecutive Officer, Director
  • ALEXANDER WENDLANDExecutive Officer, Director
  • DEAN A. TRAVERSExecutive Officer, Director
Offering amount
$700K
Amount sold
$410K
First sale
Oct 2016
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$250KraisedJul 2016 · 7 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • DEAN A. TRAVERSExecutive Officer, Director
  • SCOTT XIAOExecutive Officer, Director
  • ALEXANDER WENDLANDExecutive Officer, Director
Offering amount
$500K
Amount sold
$250K
First sale
Jul 2016
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.